Abstract. BACKGROUND: Tumor-infiltrating lymphocytes (TILs) have a strong prognostic value in various forms of cancers. These data often refer to use of the pan-T cell marker CD3, or the cytotoxic T lymphocyte marker CD8α. However, T cells are a heterogeneous group of cells with a wide array of effector mechanisms ranging from immunosuppression to cytotoxicity. OBJECTIVE: In this study we have investigated the prognostic effects of some unconventional T cell subtypes in breast cancer; γδ T cells, IL-17 + T cells and FoxP3 + T cells (Tregs) in relation to the conventional CD3 and CD8α T cell markers. METHODS: This was done using immunohistochemistry on a human breast cancer tissue microarray consisting of 498 consecutive cases of primary breast cancer. RESULTS: Infiltration of γδ T cells and T cell infiltration in general (CD3), correlated with a good prognosis, while Treg infiltration with a worse. Infiltration of γδ T cells was associated with a significantly improved clinical outcome in all breast cancer subtypes except triple negative tumors. Only infiltration of either CD3 + or CD8α + cells was independently associated with better prognosis for all breast cancer patients. CONCLUSIONS: This study sheds further light on the prognostic impact of various T cell subtypes in breast cancer.
Introduction
Breast cancer is a heterogeneous disease consisting of different subtypes with varying prognosis [1] . It is however not only the breast cancer subtype that determines the prognostic outcome, but also the tumor microenvironment cell composition [2] . The cells of the immune system are an important part of the tumor microenvironment, where presence of tumor infiltrating lymphocytes (TILs) usually is associated with a better prognosis, while infiltration of myeloid cells is associated with a worse prognosis [3] . T lymphocytes is an important TIL population [3] . In breast cancer, infiltration of T cells has been linked to different outcomes in different breast cancer subtypes. In HER2 + and triple negative breast cancers (TNBCs; ER − PR − HER2 − ), infiltration of T cells has been associated with an improved prognosis [4] , a finding that was even more evident in patients receiving neoadjuvant chemotherapy [5] [6] [7] . It has been postulated that this effect may be due to tumor cell death and expression of neoantigens that initiate tumoricidal immune responses [8, 9] .
T cells can grossly be divided into cytotoxic T lymphocytes (CTLs; CD8 + ), T helper cells (T h [T h1 , T h2 , T h9 , T FH , T h17 and T regs ]; CD4 + ), γδ T cells and NKT cells [10] . Regulatory T cells (T regs ) are defined as CD4
+ CD25 + FoxP3 + T cells, and T h17 cells as CD4 + RORγt + T cells with high production of the proinflammatory cytokine; IL-17A [10, 11] . T regs are associated with immune suppression [12] and infiltration of T regs in ER + breast cancers has been shown to correlate with a worse prognosis [4, 13] , while studies regarding the prognostic effects of T h17 infiltration in breast cancer are limited [14] [15] [16] . When it comes to CTLs, infiltration of CD8 + lymphocytes does not seem to have a prognostic impact in ER + breast cancer, but has been shown to correlate with an improved breast cancer specific survival (BCSS) in ER-negative tumors [17] . γδ T cells are unconventional T cells that express invariant, canonical TCRγ and TCRδ chains. They are either CD4 − CD8 − or express CD8αα + homodimers, and recognize antigen in an MHC/HLA independent manner [18] . The fact that γδ T cells often express CD8 puts previous studies concerning the prognostic value of CD8 + CTLs in breast cancer in a different light. γδ T cells are T cells with dual functions and can thus be both tumor promoting and suppressing [19] . In breast cancer, γδ T cell infiltration was reported to be associated with the HER2 subtype and poor prognosis in a small patient cohort [20] . However, contrasting data have been shown in recent publications where elevated expression levels of genes associated with γδ T cells had a positive impact on patient survival [21, 22] .
There are many reports concerning the prognostic and predictive impact of infiltrating T cells on breast cancer survival, but often only CD3, CD8 or FoxP3-positive T cells have been evaluated [23] . Furthermore, the T cell subpopulations γδ T cells, T h17 cells and T regs all have been reported to have dual and opposing effects in different tumor types, therefore making them important to study for each cancer type [24, 25] . Also, the presence of IL-17 + γδ T cells has lately been proposed thus complicating the T h17 nomenclature [26] . In this study, we therefore decided to evaluate the prognostic impact of infiltrating γδ T cells, IL-17 + T cells and FoxP3 + T cells (T regs ), as compared to the conventional TIL markers CD8α
+ and CD3 + T cells, in tumors from a retrospective, consecutive cohort of 498 patients with primary breast cancer [27] . Our findings highlight the prognostic effect of each T cell subpopulation in breast cancer and will be important for the future understanding and use of novel drugs like immune checkpoint inhibitors in this disease.
Materials and methods

Breast cancer patients
The study cohort has been previously described [27] [28] [29] [30] 
TMA, immunohistochemistry and staining assessment
Tissue microarrays (TMA) were constructed as previously described [27] [28] [29] [30] . Analysis of ER, PR and HER2 status of the tumors in the TMA, was performed according to current Swedish guidelines. For antibodies and staining procedures see Supplementary Table 2. Anti-TCRγ specificity was evaluated using sorted peripheral blood γδ T cells as positive control (Supplementary Fig. 1 ). CD3 and TCRγ were manually annotated using a semiquantitative scoring system and denoted as 0 = none, 1 = low, 2 = moderate and 3 = high in each core. CD8 had been scored previously [31] . The total number of IL-17 and FoxP3 positive cells with lymphocytic morphology was an- notated in each core using automated image analysis (Halo image analysis software, Indica Labs, Corrales, NM, USA). The total number of positive cells was then manually categorized as 0 = none, 1 = low, 2 = moderate and 3 = high. The core with the highest number of positive cells within each case was used in the subsequent statistical analyses.
Statistical analysis
Spearman's Rho test was applied using non-dichotomized CD3, TCRγ, FoxP3 and IL-17 scoring for associations between T cell populations and breast cancer subtypes. For all other analyses dichotomized variables were constructed; CD3 was dichotomized into low (0, 1) or high (2, 3), TCRγ into absence (0) or presence (1, 2, 3), FoxP3 into low (0, 1) or high (2, 3) and IL-17 into low (0, 1) or high (2, 3). Pearson χ 2 -test was used for crosstabs. Kaplan-Meier analysis was used to evaluate the impact of different T cell populations on breast cancer specific survival (BCSS) and recurrence free survival (RFS). Log rank test was applied to analyze any significant differences in KaplanMeier survival plots. Cox regression proportional hazards analysis was used to obtain hazard ratios (HR) for BCSS and RFS according to CD8α, CD3, TCRγ, FoxP3 and IL-17 density in both uni-and multivariable analysis, adjusted for dichotomized clinicopathological parameters (age, lymph node metastasis, tumor size, Nottingham histological grade [NHG] , ER status, HER2 status, triple negative, luminal A and luminal B), and Ki67. All P values were two-tailed. P value 0.05 was considered significant. All calculations and statistical analyses were performed with IBM SPSS Statistics version 23.0 (SPSS Inc).
Results
Infiltration of alternative T cell subpopulations
and associations to molecular subtypes of primary breast cancer
Representative staining patterns of the analyzed T cell-subpopulations and correlations between different T cell populations and breast cancer subtypes are shown in Fig. 1a and Supplementary Fig. 1 .
As shown in Table 1 , infiltration of CD8α positive cells correlated positively with TNBC and inversely with ER-positive breast cancers. Infiltration of both CD3 and γδ T cells was associated with TNBC and HER2
+ breast cancers, but inversely associated with both the luminal A subtype as well as with ER-positive breast cancers. T reg infiltration was associated with the TNBC and HER2
+ breast cancers, but inversely associated with both the luminal A subtype and ER-positive breast cancers. IL-17 + T cell infiltration was inversely associated with the TNBC subtype. It is known that γδ T cells can express CD8αα homodimers [18] , but also IL-17A and the transcription factor FoxP3 [19] . As shown in Table 2 , there was a significant correlation between CD8α and γδ TCR (p = 0.003), as well as for FoxP3 and γδ TCR (p 0.001), but not with IL-17 expression and γδ TCR ( Table 2 ).
Prognostic significance of alternative T cell subpopulations in the entire cohort
We next investigated the prognostic impact of individual T cell subsets (CD3, CD8α + , γδ T cells, T regs and IL-17 + T cells) on BCSS and RFS in the entire cohort. Kaplan-Meier analysis revealed that tumor infiltration of any kind of T cells (CD3) correlated with a significantly improved BCSS and RFS (Fig. 1B) . There was no significant association between CD8α + lymphocyte infiltration and BCSS or RFS. γδ T cell infiltration was associated with a significantly prolonged BCSS and RFS. In contrast, T regs were associated with poor BCSS, while IL-17 + T cells did not have any prognostic impact (Fig. 1B) .
Univariable Cox regression analysis showed that presence of T cells (CD3), had an overall significant positive impact on BCSS (HR = 0.56; 95% CI = 0.35-0.89; p = 0.015) and RFS (HR = 0.50; 95% CI = 0.35-0.72; p 0.001). This was also true for γδ T (Table 3) .
When adjusted for clinicopathological parameters and not receiving adjuvant endocrine therapy. The study cohort was conceived before clinical use of ER-testing, hence both groups includes both ER-positive and ER-negative patients. Log-rank P value < 0.05 was considered significant.
Prognostic value of alternative T cell subpopulations according to breast cancer subtype
Kaplan-Meier analyses were also performed in strata according to different subtypes of breast cancer. This revealed that tumor infiltration of T cells overall (CD3) was associated with an improved prognosis specifically in Luminal A and ER-positive breast cancers (BCSS and RFS; Figs 2 and 3) . CD8α
+ and γδ T cell lymphocyte infiltration was associated with a prolonged BCSS only in the HER2 + breast cancers (Fig. 2) , and interestingly, 20 out of 23 HER2
+ cases scored positive for both CD8α
+ and γδ T cell infiltration (p 0.001; Table 2 ). Importantly, γδ T cell infiltration was associated with an improved RFS in Luminal A, Luminal B, HER2 and ER-positive breast cancers (Fig. 3) . Tumor infiltration of T regs was associated with a poor BCSS only in ER-positive breast cancers (Fig. 2) . In contrast, infiltration of IL-17 + T cells was associated with a poor RFS in TNBCs (Fig. 3) .
Prognostic impact of T cell infiltration in relation to endocrine therapy
Next, we evaluated whether tumor infiltration of different T cell populations had any impact on prognosis in relation to endocrine therapy. The study cohort was conceived before clinical use of ER-testing, hence both groups include both ER-positive and ER-negative patients [27] . Kaplan-Meier analysis in strata according to treatment revealed that tumor infiltration of CD8α + T cells only had a positive impact on BCSS and RFS in the treated group (Fig. 2B) . CD3, however, was significantly associated with a prolonged RFS in the treated group, and with a prolonged BCSS and RFS in the untreated group (Fig. 4) . Infiltration of γδ T cells was significantly associated with an improved BCSS in patients receiving adjuvant treatment, and with a significantly improved RFS, but not BCSS, in the untreated group (Fig. 4) . Infiltration of T regs in tumors of untreated patients was significantly associated with a poor outcome on BCSS, while IL-17 + T cells showed no impact on BCSS or RFS in either group (Fig. 4) .
Univariable Cox regression analysis of the endocrine therapy treated group revealed that CD8α + T cell infiltration was associated with an improved BCSS (HR = 0.47; 95% CI = 0.25-0.88; p = 0.019) and RFS (HR = 0.58; 95% CI = 0.34-0.99; p = 0.044). In the endocrine therapy untreated group, CD3 was associated with improved BCSS (HR = 0.35; 95% CI = 0.14-0.87; p = 0.023) and RFS (HR = 0.36; 95% CI = 0.20-0.68; p = 0.002), while in the endocrine therapy treated patient group, CD3 was associated only with a prolonged RFS (HR = 0.59; 95% CI = 0.35-0.99; p = 0.046; Table 3 ). Presence of tumor infiltrating γδ T cells was significantly associated with an improved RFS in the untreated group only (HR = 0.46; 95% CI = 0.24-0.89; p = 0.021) while T regs were significantly associated with an impaired BCSS (HR = 2.59; 95% CI = 1.00-6.67; p = 0.050; Table 3 ).
In endocrine therapy treated patients, CD8α + T cells remained an independent prognostic factor for a prolonged BCSS and RFS in multivariable Cox regression analysis (HR = 0.21; 95% CI = 0.09-0.52; p = 0.001 and HR = 0.41; 95% CI = 0.20-0.84; p = 0.014, respectively; Table 5 ). Infiltration of γδ T cells was independently associated with an improved BCSS (HR = 0.32; 95% CI = 0.12-0.82; p = 0.018; Table 5 ) only in endocrine therapy treated patients. In endocrine therapy untreated patients, however, CD3 was an independent factor of a prolonged BCSS (HR = 0.03; 95% CI = 0.00-0.24; p = 0.001) and RFS (HR = 0.21; 95% CI = 0.07-0.64; p = 0.006), whereas presence tumor infiltrating T regs was revealed to be an independent factor of an impaired BCSS (HR = 17.31; 95% CI = 2.45-122.16; p = 0.004; Table 6 ).
Discussion
In this study, we investigated the prognostic value of infiltrating γδ T cells, T regs and IL-17 + T cells, as compared to the common TIL markers CD3 and CD8α, in invasive breast cancer. The analyses were also performed in relation to adjuvant endocrine therapy.
We show that infiltration of T cells (CD3) had a positive effect on prognostic outcome in breast cancer, which supports previous studies evaluating TILs as a prognostic parameter. However, since CD3 is a pan-T cell marker, further investigation was needed to identify specific T cell subtypes that may play a role in breast cancer progression and as potential responders to immune-therapies.
The only T cell subpopulation with results similar to that of CD3, turned out to be γδ T cells that were associated with an improved survival in general. When stratified according to breast cancer subtype, infiltration of γδ T cells was the only T cell population that correlated with a positive outcome in all subtypes (luminal A, luminal B, HER2-positive and ER-positive breast cancers), except TNBCs. It is likely that the TNBC environment not only recruits more γδ T cells, but also has a negative effect on γδ T cell activity. This is a controversy that would merit further investigation at the functional level in the future.
In multivariable Cox regression analyses however, both CD3 and CD8α + T cell infiltration remained independent factors of a prolonged BCSS as well as RFS. Interestingly, in contrast to general T cell infiltration (CD3), both infiltrating CD8α + and γδ T cells were revealed to be independent prognostic factors in patients receiving endocrine treatment. The fact that several immune cells can express CD8α, including γδ T cells, makes it difficult to evaluate whether it is conventional CTLs that has the major effect on prognosis in our investigation [32] [33] [34] [35] . Some studies have proposed that γδ T cells can acquire both pro-or anti-tumor properties depending on the tumor microenvironment [25] . Furthermore, the regulation of γδ T cells by inhibitory co-receptors is slightly different as compared to conventional αβ T cells [36, 37] . Indeed, the majority of tumors that scored positive for γδ T cell infiltration in our cohort also scored positive for CD8α + T cells and these may therefore be γδ T cells, rather than conventional TCR αβ + CTLs. This was especially clear in the HER2 group, however, due to the small size of this patient group no conclusions should be drawn. In line with our findings, it has already been shown that γδ T cell gene expression signatures were associated with a favorable prognosis across multiple malignancies, also in breast cancer [21, 22] . In the herein studied cohort, infiltration of T regs was associated with a worse prognosis, but not in multivariable Cox regression analyses. When stratified according to breast cancer subtypes it was revealed that infiltration of T regs was associated with worse prognosis primarily in ER-positive breast cancers, indicating that T regs could serve as a potential therapeutic target in ER-positive breast cancers specifically. Also, a significant association between presence of FoxP3 + and γδ T cells was found. However, the fact that the prognostic impact of infiltrating γδ T cells and T regs was contradictory suggests that these are not regulatory FoxP3 + γδ T cells [38] . We show that infiltration of IL-17 + T cells in general has no prognostic impact. However, when stratified according to breast cancer subtype it was revealed that infiltration of IL-17 + T cells was associated with a worse prognosis in TNBC, specifically. TNBCs often produce inflammatory mediators and it is likely that T h17 cells are either attracted to or even play a role in regulating the TNBC microenvironment [39] . Studies on the clinical relevance of T h17 infiltration in breast tumors has been performed previously, but on small patient cohorts and with opposing results [14] [15] [16] 40] . Nonetheless, these studies point out the complex nature of T h17 cell behavior in a tumor context. Tumor infiltrating T h17 cells have been associated with both tumor promoting and inhibiting properties [39] . Indeed, reports investigating the plasticity of T h17 in breast cancer have shown that T h17 even might be immunosuppressive [16, 41] . Lately, the presence of IL-17 + γδ T cells that promotes myeloid cell accumulation and polarization has been reported as an important mechanism in breast cancer progression and metastasis in mice [26] and supporting evidence was recently shown also for human colorectal cancers [42] . The strength of our study lies in the size of the breast cancer cohort, but also that IL-17 + T cell and γδ T cell infiltration was analyzed in parallel. We found no correlation between presence of IL-17 + cells and γδ T cells in this study.
Conclusions
In conclusion, our results demonstrate that in breast cancer, infiltration of T cells (CD3) and γδ T cells are associated with good clinical outcome, while T regs are associated with worse clinical outcome. Infiltration of γδ T cells was associated with a significantly improved prognosis in all breast cancer subtypes except TNBC. However, when adjusted for clinicopathological parameters, only CD8α T cells and CD3 infiltration proved to be independently associated with clinical outcome. Furthermore, except for CD3, infiltration of γδ T cells was the only marker that correlated with an improved clinical outcome in both endocrine treated and untreated patients. When adjusted for clinicopathological parameters, both CD8α T cells and γδ T cell infiltration was independently associated with an improved prognosis for patients receiving adjuvant endocrine therapy, while CD3 and T reg infiltration was associated with clinical outcome in untreated patients. Finally our findings indicate that in breast tumors, the infiltrating CD8α + T cells may indeed be γδ T cells, which merit further investigation concerning regulation and checkpoint inhibitors. This study renders new light on previously unexplored aspects of tumor infiltrating lymphocytes, and highlights potential prognostic aspects of γδ T cells, IL-17 + T cells and T regs in breast cancer, with particular reference to molecular subtypes and endocrine adjuvant treatment.
